Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

277

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

December 31, 2010

Conditions
Type 2 Diabetes
Interventions
DRUG

Salsalate

Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided

DRUG

Placebo

Placebo to Salsalate

Trial Locations (16)

10032

Columbia University, New York

11042

North Shore Diabetes and Endocrine Associates, New Hyde Park

14226

Kaleida Health Center, Buffalo

14642

University of Rochester Medical Center, Rochester

27599

University of North Carolina, Chapel Hill

30084

Kaiser Permanente, Atlanta

30303

Emory School of Medicine, Atlanta

32746

Endocrine Clinical Research, Winter Park

60612

University of Illinois at Chicago, Chicago

63110

Washington University School of Medicine, St Louis

68105

University of Nebraska Medical Center, Omaha

70112

Tulane University, New Orleans

75390

University of Texas Southwestern, Dallas

06511

Chapel Medical Group, New Haven

20003-4393

MedStar Research Institute, Washington D.C.

02215

Joslin Diabetes Center, Boston

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Joslin Diabetes Center

OTHER

NCT00392678 - Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D) | Biotech Hunter | Biotech Hunter